Centre for Liver and Digestive Disorders, the Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, Scotland, United Kingdom.
World J Gastroenterol. 2013 Jun 28;19(24):3726-46. doi: 10.3748/wjg.v19.i24.3726.
The introduction of capsule endoscopy (CE) in clinical practice increased the interest for the study of the small-bowel. Consequently, in about 10 years, an impressive quantity of literature on indications, diagnostic yield (DY), safety profile and technical evolution of CE has been published as well as several reviews. At present time, there are 5 small-bowel capsule enteroscopy (SBCE) models in the worldwide market. Head-to-head trials have showed in the great majority of studies comparable results in terms of DY, image quality and completion rate. CE meta-analyses formed the basis of national/international guidelines; these guidelines place CE in a prime position for the diagnostic work-up of patients with obscure gastrointestinal bleeding, known and/or suspected Crohn's disease and possible small-bowel neoplasia. A 2-L polyethylene glycol-based purge, administered the day before the procedure, is the most widely practiced preparation regimen. Whether this regimen can be further improved (i.e., by further decreasing its volume, changing the timing of administration, coupling it with prokinetics and/or other factors) or if it can really affect the DY, is still under discussion. Faecal calprotectin has been used in SBCE studies in two settings: in patients taking non-steroidal anti-inflammatory drugs, to evaluate the type and extent of mucosal damage and, more importantly from a clinical point of view, in patients with known or suspected Crohn's disease for assessment of inflammation activity. Although there is still a lot of debate around the exact reasons of SBCE poor performance in various small-bowel segments, it is worth to remember that the capsule progress is non-steerable, hence more rapid in the proximal than in lower segments of the small-bowel. Capsule aspiration, a relatively unexpected complication, has been reported with increasing frequency. This is probably related with the increase in the mean age of patients undergoing CE. CE video review is a time-consuming procedure. Therefore, several attempts have been made to develop technical software features, in order to make CE video analysis easier and shorter (without jeopardizing its accuracy). Suspected Blood Indicator, QuickView and Fujinon Intelligent Chromo Endoscopy are some of the software tools that have been checked in various clinical studies to date.
胶囊内镜(CE)在临床实践中的引入增加了人们对小肠研究的兴趣。因此,在大约 10 年的时间里,发表了大量关于 CE 的适应证、诊断率(DY)、安全性和技术发展的文献,以及一些综述。目前,全球市场上有 5 种小肠胶囊内镜(SBCE)模型。头对头试验表明,在大多数研究中,DY、图像质量和完成率方面的结果相当。CE 荟萃分析为国家/国际指南奠定了基础;这些指南将 CE 置于诊断不明胃肠道出血、已知和/或疑似克罗恩病和可能的小肠肿瘤患者的首要位置。在检查前一天服用 2 升基于聚乙二醇的冲洗剂是最广泛应用的准备方案。这种方案是否可以进一步改进(即通过进一步减少其体积、改变给药时间、与促动力药结合使用等),或者它是否真的可以影响 DY,仍在讨论中。粪便钙卫蛋白在 SBCE 研究中被用于两种情况:在服用非甾体抗炎药的患者中,评估黏膜损伤的类型和程度,更重要的是,从临床角度来看,在已知或疑似克罗恩病的患者中,评估炎症活动。尽管在各种小肠段中 SBCE 性能不佳的确切原因仍存在很多争议,但值得记住的是,胶囊的推进是非可控的,因此在小肠的近端比在较低部位更快。胶囊吸入是一种相对意外的并发症,其报道频率越来越高。这可能与接受 CE 检查的患者平均年龄增加有关。CE 视频审查是一个耗时的过程。因此,为了使 CE 视频分析更容易和更短(不影响其准确性),已经尝试开发了几种技术软件功能。可疑血液指标、QuickView 和富士能智能染色内镜是迄今为止在各种临床研究中检查过的一些软件工具。